The BIOSECURE Paradox: Policy Says Pull Back, Industry Is Pushing Forward

The BIOSECURE Act became law at the end of 2025. Its intent is clear: reduce the U.S. pharmaceutical industry's dependence on Chinese biotechnology companies, particularly for manufacturing, contract research, and supply chain services. WuXi AppTec was recently added to the Department of Defense's 1260H list of Chinese military companies, triggering restrictions under the Act. New legislation introduced in June 2026, the Biotech Investment National Security Act (BINSA), would expand those restrictions further into outbound investment.

At the same time, the pharmaceutical industry is moving in the opposite direction. In the first five months of 2026 alone, more than $43 billion has been committed to partnerships with Chinese biotech and pharmaceutical companies. AstraZeneca, Pfizer, and Bristol Myers Squibb have each allocated more than $16 billion to Chinese collaborations since the start of 2025. Pfizer closed a $10.5 billion deal with Innovent Biologics in May. Chinese-origin deals, which represented roughly 5% of large pharma licensing activity in 2021, crossed the majority threshold in early 2026.

These two realities are running in parallel. Policy is tightening. Capital is flowing. And supply chain teams are caught in the middle, trying to plan around a landscape where the rules and the market are moving in opposite directions.

Why the Deals Keep Happening

The scale of investment into Chinese biotech partnerships isn't happening because companies are ignoring the regulatory environment. It's happening because the innovation coming out of China is increasingly difficult to replicate elsewhere at the same speed, cost, or capability.

China's biotech sector has matured rapidly. Chinese companies are producing novel molecules, running large-scale clinical programs, and building manufacturing capabilities that compete with or exceed what's available in other markets. For large pharmaceutical companies under pressure to replenish their pipelines, Chinese biotech offers access to innovation at a pace and price point that's hard to match.

On the manufacturing side, the numbers are equally striking. Studies indicate that up to 79% of biopharmaceutical organizations are engaged with a Chinese contract manufacturing organization or contract development and manufacturing organization. That level of integration didn't happen overnight, and it doesn't unwind overnight either. The capabilities, the capacity, the cost structure, and the established relationships represent years of investment on both sides.

Companies aren't making these deals carelessly. The BIOSECURE Act has changed how partnerships are structured. There's more diligence around supply chains, data access, technology transfers, and contractual exit rights. Deals are more complex, with additional safeguards built in to preserve flexibility if the geopolitical environment shifts further. But the deals themselves aren't slowing down.

What BIOSECURE Actually Restricts

It's worth being precise about what the BIOSECURE Act does and doesn't do, because the perception and the reality don't always align.

The Act restricts federal procurement, contracting, grants, and loans involving biotechnology products or services from designated "biotechnology companies of concern." It doesn't broadly prohibit U.S. companies from working with Chinese partners. It targets specific entities on the Department of Defense's 1260H list and creates consequences for companies that maintain those relationships while also doing business with the U.S. government.

There's a five-year safe harbor for existing contracts with companies that are later designated under the list. And the Act's enforcement mechanisms are focused on the federal procurement nexus, not on private commercial activity broadly.

That distinction matters for supply chain planning. A company whose revenue is heavily dependent on Medicare and Medicaid reimbursement faces a very different calculus than a company operating primarily in private or international markets. The risk isn't uniform across the industry, and the response shouldn't be either.

That said, the trajectory of the legislation is clear. BINSA would expand restrictions into outbound investment. The 1260H list continues to be updated. The political appetite for additional restrictions on Chinese biotech relationships shows no signs of decreasing. Companies that assume the current rules represent the ceiling of what's coming may be underestimating where this is headed.

The Supply Chain Dilemma

For supply chain leaders, this creates a genuinely difficult planning environment. The strategic direction from policy is to reduce Chinese dependency. The operational reality is that alternatives don't exist at the scale and capability many companies need, at least not yet. And the commercial side of the business is actively expanding Chinese partnerships because the science and the economics are compelling.

Transitioning manufacturing from an established Chinese CDMO to a domestic or non-Chinese partner is not a decision that gets made in a quarter. It's a multi-year undertaking involving tech transfers, regulatory filings, process validation, and significant capital investment. For complex biologics, the timeline can be even longer. These are the same operational realities we explored in the reshoring conversation, and they haven't changed.

What has changed is the urgency. Companies that haven't started evaluating their Chinese supply chain exposure are running out of runway to do so at their own pace. The regulatory environment is tightening incrementally, and each incremental step narrows the window for a measured, well-planned transition.

At the same time, companies that overreact and try to sever Chinese partnerships prematurely risk disrupting their own supply chains, losing access to capabilities they can't easily replace, and spending capital on transitions that may not be necessary depending on how the regulatory landscape evolves.

Planning in Both Directions

The companies I've seen navigate this most effectively are doing something that sounds contradictory: they're planning for both outcomes simultaneously. They're maintaining their current Chinese partnerships where the science and the business case are strong, while quietly building optionality to transition if the regulatory environment requires it.

In practice, that looks like mapping your current supply chain exposure to Chinese partners in detail, not just the obvious CDMO relationships but also raw material suppliers, testing labs, and component manufacturers. It means identifying which of those relationships could be transitioned to non-Chinese alternatives and what the timeline and cost of each transition would actually be. And it means building that analysis into your supply chain strategy now, so that if a regulatory trigger forces action, you're executing a plan rather than scrambling.

It also means watching the regulatory landscape actively, not passively. The 1260H list gets updated. New legislation gets introduced. Enforcement guidance gets issued. Supply chain teams that are tracking these developments in real time can adjust proactively. Teams that aren't will find themselves reacting to headlines.

The Tension Isn't Going Away

There's no clean resolution to the paradox of policy pushing in one direction while capital flows in the other. The pharmaceutical industry's relationship with Chinese biotech is deep, valuable, and increasingly complicated. The policy environment is tightening, but the market forces driving these partnerships are strong enough that $43 billion in deals happened in five months, after the BIOSECURE Act was already law.

For supply chain leaders, the job isn't to predict which force will win. It's to build enough flexibility into the supply chain to adapt regardless of which direction the landscape moves. That requires honest assessment of current exposure, realistic planning for potential transitions, and the organizational discipline to prepare for scenarios that may or may not materialize.

The companies that will be best positioned are the ones doing that work now, while they still have time to do it thoughtfully.

Verant Consulting Group helps biotech companies navigate supply chain strategy in a shifting regulatory and geopolitical landscape. If you're evaluating your Chinese supply chain exposure or building contingency plans, let's talk.